Regeneron Pharmaceuticals Faces Class Action Lawsuit Following Disappointing Trial Results#USA#San_Francisco#Regeneron_Pharmaceuticals#Hagens_Berman#Phase_3_Trial
Regeneron Pharmaceuticals Faces Class Action Lawsuit Following Disappointing Trial Results
Investors of Regeneron Pharmaceuticals (NASDAQ: REGN) are alerted about a class action lawsuit due to failed Phase 3 trial results impacting share values.
third-news.com
August 14, 2026 at 7:50 PM
Regeneron Pharmaceuticals Faces Class Action Lawsuit Following Disappointing Trial Results#USA#San_Francisco#Regeneron_Pharmaceuticals#Hagens_Berman#Phase_3_Trial
Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment#Sweden#Stockholm#Diamyd_Medical#Phase_3_Trial#retogatein
Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment
Diamyd Medical has entered into financing agreements with U.S. investors totaling $125 million and announced full enrollment in its Phase 3 trial.
third-news.com
March 23, 2026 at 7:36 AM
Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment#Sweden#Stockholm#Diamyd_Medical#Phase_3_Trial#retogatein
Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion#Sweden#Stockholm#Diamyd_Medical#Phase_3_Trial#retogatein
Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion
Diamyd Medical announces successful financing agreements totaling $125 million and the completion of its Phase 3 clinical trial for Type 1 diabetes.
third-news.com
March 23, 2026 at 7:35 AM
Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion#Sweden#Stockholm#Diamyd_Medical#Phase_3_Trial#retogatein
GC Biopharma Initiates Phase 3 Clinical Trial for BARYCELA Vaccine in Thailand#South_Korea#GC_Biopharma#Yongin#Phase_3_Trial#BARYCELA
GC Biopharma Initiates Phase 3 Clinical Trial for BARYCELA Vaccine in Thailand
GC Biopharma has submitted an IND for a Phase 3 trial of BARYCELA, a varicella vaccine, aiming for approval in Southeast Asia by 2027.
third-news.com
August 28, 2025 at 6:25 AM
GC Biopharma Initiates Phase 3 Clinical Trial for BARYCELA Vaccine in Thailand#South_Korea#GC_Biopharma#Yongin#Phase_3_Trial#BARYCELA
Moleculin Biotech Strengthens Global Patent Portfolio for Annamycin, Aiming for Next-Gen Cancer Treatment#USA#Houston#Moleculin_Biotech#Annamycin#Phase_3_Trial
Moleculin Biotech Strengthens Global Patent Portfolio for Annamycin, Aiming for Next-Gen Cancer Treatment
Moleculin Biotech has secured additional patent allowances for Annamycin, aiming to enhance its global exclusivity and expedite clinical trials for cancer therapies.
third-news.com
March 6, 2025 at 1:48 PM
Moleculin Biotech Strengthens Global Patent Portfolio for Annamycin, Aiming for Next-Gen Cancer Treatment#USA#Houston#Moleculin_Biotech#Annamycin#Phase_3_Trial